

Remarks

Claims 1-28 are being cancelled and new claims 29-43.

Applicants request amendment of the claims in order to bring the claims into compliance with U.S. practice. The claims read on piperidine compounds which are the compounds disclosed and described in the Specification. Previous amendments in prior applications to pyrrolidine compounds were incorrect and are not considered part of patent application.

Applicants request an amendment on page 10 of the Specification in the section "title". Applicants noted that the compound labeled "C" on page 10 is 2-[n-(1-hydroxyundecyl)]piperidine because there are eleven carbons in the side chain. The "title" of the section in the Specification inadvertently named the compound labeled "C" as 2-(n-decylhydroxy)piperidine which is incorrect because 2-(n-decylhydroxy)piperidine has ten carbons in the side chain. Applicants apologize for this error. No new matter is being added with the correction of this obvious but inadvertent error.

Applicants request an amendment to the first page of the Specification so that the parent applications are listed and priority claim can be ascertained. No new matter is being added.

Please enter the above amendment before calculating the fees and examining the present application.

This application is being filed after a response to the parent application (10/106,004) has been filed. There are no pending Office Actions in the parent application. Therefore, no fee other than the filing fee is believed to be required, however, the Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-0134.

Applicants request that all correspondence be directed to the address associated with Customer Number 001095 which is currently as follows:

Thomas Hoxie
Novartis
Corporate Intellectual Property
One Health Plaza, Building 430
East Hanover, NJ 07936-1080

Any questions or issues can be directed to the below signed attorney at this address.
Thank you for your assistance with this matter.

Novartis
Corporate Intellectual Property
One Health Plaza, Building 430
East Hanover, NJ 07936-1080
(862) 778-7922

Respectfully submitted,

A handwritten signature in black ink, appearing to read "David L. Marks", is written over a horizontal line.

David L. Marks
Attorney for Applicants
Reg. No. 37,881

Date: January 2, 2004